The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Chronic Liver Diseases Therapeutics Market 2024 by Company, Regions, Type and Application, Forecast to 2028
Synopsis
The Chronic Liver Diseases Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Chronic Liver Diseases Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital Pharmacies accounting for % of the Chronic Liver Diseases Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Chemotherapy Drugs segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Chronic Liver Diseases Therapeutics include Astellas Pharma, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, and F. Hoffmann-La Roche, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chronic Liver Diseases Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chemotherapy Drugs
Targeted Therapy
Vaccines
Antiviral Drugs
Immunoglobulins
Corticosteroids
Others
Market segment by Application, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by players, this report covers
Astellas Pharma
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
F. Hoffmann-La Roche
Merck
Novartis
Sanofi
Pfizer
Takeda Pharmaceutical
Bausch Health
Theratechnologies
Alnylam Pharmaceuticals
Protagonist Therapeutics
Dicerna Pharmaceuticals
Endo International
Provectus Biopharmaceuticals
MAX BioPharma
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Chronic Liver Diseases Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Chronic Liver Diseases Therapeutics, with revenue, gross margin and global market share of Chronic Liver Diseases Therapeutics from 2019 to 2022.
Chapter 3, the Chronic Liver Diseases Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Chronic Liver Diseases Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Chronic Liver Diseases Therapeutics research findings and conclusion, appendix and data source.
Geographical Area
Global
The Chronic Liver Diseases Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Chronic Liver Diseases Therapeutics market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of USD million by 2028 with a CAGR of % during review period. Hospital Pharmacies accounting for % of the Chronic Liver Diseases Therapeutics global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Chemotherapy Drugs segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Chronic Liver Diseases Therapeutics include Astellas Pharma, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, and F. Hoffmann-La Roche, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Chronic Liver Diseases Therapeutics market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chemotherapy Drugs
Targeted Therapy
Vaccines
Antiviral Drugs
Immunoglobulins
Corticosteroids
Others
Market segment by Application, can be divided into
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Market segment by players, this report covers
Astellas Pharma
Bristol-Myers Squibb
Gilead Sciences
GlaxoSmithKline
F. Hoffmann-La Roche
Merck
Novartis
Sanofi
Pfizer
Takeda Pharmaceutical
Bausch Health
Theratechnologies
Alnylam Pharmaceuticals
Protagonist Therapeutics
Dicerna Pharmaceuticals
Endo International
Provectus Biopharmaceuticals
MAX BioPharma
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
The content of the study subjects, includes a total of 12 chapters:
Chapter 1, to describe Chronic Liver Diseases Therapeutics product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Chronic Liver Diseases Therapeutics, with revenue, gross margin and global market share of Chronic Liver Diseases Therapeutics from 2019 to 2022.
Chapter 3, the Chronic Liver Diseases Therapeutics competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Chronic Liver Diseases Therapeutics market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Chronic Liver Diseases Therapeutics research findings and conclusion, appendix and data source.
Geographical Area
Global
Index1 Market Overview
1.1 Product Overview and Scope of Chronic Liver Diseases Therapeutics
1.2 Classification of Chronic Liver Diseases Therapeutics by Type
1.2.1 Overview: Global Chronic Liver Diseases Therapeutics Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Chronic Liver Diseases Therapeutics Revenue Market Share by Type in 2021
1.2.3 Chemotherapy Drugs
1.2.4 Targeted Therapy
1.2.5 Vaccines
1.2.6 Antiviral Drugs
1.2.7 Immunoglobulins
1.2.8 Corticosteroids
1.2.9 Others
1.3 Global Chronic Liver Diseases Therapeutics Market by Application
1.3.1 Overview: Global Chronic Liver Diseases Therapeutics Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Global Chronic Liver Diseases Therapeutics Market Size & Forecast
1.5 Global Chronic Liver Diseases Therapeutics Market Size and Forecast by Region
1.5.1 Global Chronic Liver Diseases Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Chronic Liver Diseases Therapeutics Market Size by Region, (2017-2022)
1.5.3 North America Chronic Liver Diseases Therapeutics Market Size and Prospect (2017-2028)
1.5.4 Europe Chronic Liver Diseases Therapeutics Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Chronic Liver Diseases Therapeutics Market Size and Prospect (2017-2028)
1.5.6 South America Chronic Liver Diseases Therapeutics Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Chronic Liver Diseases Therapeutics Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Chronic Liver Diseases Therapeutics Market Drivers
1.6.2 Chronic Liver Diseases Therapeutics Market Restraints
1.6.3 Chronic Liver Diseases Therapeutics Trends Analysis
2 Company Profiles
2.1 Astellas Pharma
2.1.1 Astellas Pharma Details
2.1.2 Astellas Pharma Major Business
2.1.3 Astellas Pharma Chronic Liver Diseases Therapeutics Product and Solutions
2.1.4 Astellas Pharma Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Astellas Pharma Recent Developments and Future Plans
2.2 Bristol-Myers Squibb
2.2.1 Bristol-Myers Squibb Details
2.2.2 Bristol-Myers Squibb Major Business
2.2.3 Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Product and Solutions
2.2.4 Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.3 Gilead Sciences
2.3.1 Gilead Sciences Details
2.3.2 Gilead Sciences Major Business
2.3.3 Gilead Sciences Chronic Liver Diseases Therapeutics Product and Solutions
2.3.4 Gilead Sciences Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Gilead Sciences Recent Developments and Future Plans
2.4 GlaxoSmithKline
2.4.1 GlaxoSmithKline Details
2.4.2 GlaxoSmithKline Major Business
2.4.3 GlaxoSmithKline Chronic Liver Diseases Therapeutics Product and Solutions
2.4.4 GlaxoSmithKline Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 GlaxoSmithKline Recent Developments and Future Plans
2.5 F. Hoffmann-La Roche
2.5.1 F. Hoffmann-La Roche Details
2.5.2 F. Hoffmann-La Roche Major Business
2.5.3 F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Product and Solutions
2.5.4 F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 F. Hoffmann-La Roche Recent Developments and Future Plans
2.6 Merck
2.6.1 Merck Details
2.6.2 Merck Major Business
2.6.3 Merck Chronic Liver Diseases Therapeutics Product and Solutions
2.6.4 Merck Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Merck Recent Developments and Future Plans
2.7 Novartis
2.7.1 Novartis Details
2.7.2 Novartis Major Business
2.7.3 Novartis Chronic Liver Diseases Therapeutics Product and Solutions
2.7.4 Novartis Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Novartis Recent Developments and Future Plans
2.8 Sanofi
2.8.1 Sanofi Details
2.8.2 Sanofi Major Business
2.8.3 Sanofi Chronic Liver Diseases Therapeutics Product and Solutions
2.8.4 Sanofi Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Sanofi Recent Developments and Future Plans
2.9 Pfizer
2.9.1 Pfizer Details
2.9.2 Pfizer Major Business
2.9.3 Pfizer Chronic Liver Diseases Therapeutics Product and Solutions
2.9.4 Pfizer Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Pfizer Recent Developments and Future Plans
2.10 Takeda Pharmaceutical
2.10.1 Takeda Pharmaceutical Details
2.10.2 Takeda Pharmaceutical Major Business
2.10.3 Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Product and Solutions
2.10.4 Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Takeda Pharmaceutical Recent Developments and Future Plans
2.11 Bausch Health
2.11.1 Bausch Health Details
2.11.2 Bausch Health Major Business
2.11.3 Bausch Health Chronic Liver Diseases Therapeutics Product and Solutions
2.11.4 Bausch Health Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 Bausch Health Recent Developments and Future Plans
2.12 Theratechnologies
2.12.1 Theratechnologies Details
2.12.2 Theratechnologies Major Business
2.12.3 Theratechnologies Chronic Liver Diseases Therapeutics Product and Solutions
2.12.4 Theratechnologies Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 Theratechnologies Recent Developments and Future Plans
2.13 Alnylam Pharmaceuticals
2.13.1 Alnylam Pharmaceuticals Details
2.13.2 Alnylam Pharmaceuticals Major Business
2.13.3 Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Product and Solutions
2.13.4 Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
2.14 Protagonist Therapeutics
2.14.1 Protagonist Therapeutics Details
2.14.2 Protagonist Therapeutics Major Business
2.14.3 Protagonist Therapeutics Chronic Liver Diseases Therapeutics Product and Solutions
2.14.4 Protagonist Therapeutics Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 Protagonist Therapeutics Recent Developments and Future Plans
2.15 Dicerna Pharmaceuticals
2.15.1 Dicerna Pharmaceuticals Details
2.15.2 Dicerna Pharmaceuticals Major Business
2.15.3 Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Product and Solutions
2.15.4 Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Dicerna Pharmaceuticals Recent Developments and Future Plans
2.16 Endo International
2.16.1 Endo International Details
2.16.2 Endo International Major Business
2.16.3 Endo International Chronic Liver Diseases Therapeutics Product and Solutions
2.16.4 Endo International Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 Endo International Recent Developments and Future Plans
2.17 Provectus Biopharmaceuticals
2.17.1 Provectus Biopharmaceuticals Details
2.17.2 Provectus Biopharmaceuticals Major Business
2.17.3 Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Product and Solutions
2.17.4 Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Provectus Biopharmaceuticals Recent Developments and Future Plans
2.18 MAX BioPharma
2.18.1 MAX BioPharma Details
2.18.2 MAX BioPharma Major Business
2.18.3 MAX BioPharma Chronic Liver Diseases Therapeutics Product and Solutions
2.18.4 MAX BioPharma Chronic Liver Diseases Therapeutics Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 MAX BioPharma Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Chronic Liver Diseases Therapeutics Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Chronic Liver Diseases Therapeutics Players Market Share in 2021
3.2.2 Top 10 Chronic Liver Diseases Therapeutics Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Chronic Liver Diseases Therapeutics Players Head Office, Products and Services Provided
3.4 Chronic Liver Diseases Therapeutics Mergers & Acquisitions
3.5 Chronic Liver Diseases Therapeutics New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Chronic Liver Diseases Therapeutics Revenue and Market Share by Type (2017-2022)
4.2 Global Chronic Liver Diseases Therapeutics Market Forecast by Type (2023-2028)
5 Market Size Segment by Application
5.1 Global Chronic Liver Diseases Therapeutics Revenue Market Share by Application (2017-2022)
5.2 Global Chronic Liver Diseases Therapeutics Market Forecast by Application (2023-2028)
6 North America by Country, by Type, and by Application
6.1 North America Chronic Liver Diseases Therapeutics Revenue by Type (2017-2028)
6.2 North America Chronic Liver Diseases Therapeutics Revenue by Application (2017-2028)
6.3 North America Chronic Liver Diseases Therapeutics Market Size by Country
6.3.1 North America Chronic Liver Diseases Therapeutics Revenue by Country (2017-2028)
6.3.2 United States Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
6.3.3 Canada Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
6.3.4 Mexico Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
7 Europe by Country, by Type, and by Application
7.1 Europe Chronic Liver Diseases Therapeutics Revenue by Type (2017-2028)
7.2 Europe Chronic Liver Diseases Therapeutics Revenue by Application (2017-2028)
7.3 Europe Chronic Liver Diseases Therapeutics Market Size by Country
7.3.1 Europe Chronic Liver Diseases Therapeutics Revenue by Country (2017-2028)
7.3.2 Germany Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
7.3.3 France Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
7.3.5 Russia Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
7.3.6 Italy Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Chronic Liver Diseases Therapeutics Revenue by Type (2017-2028)
8.2 Asia-Pacific Chronic Liver Diseases Therapeutics Revenue by Application (2017-2028)
8.3 Asia-Pacific Chronic Liver Diseases Therapeutics Market Size by Region
8.3.1 Asia-Pacific Chronic Liver Diseases Therapeutics Revenue by Region (2017-2028)
8.3.2 China Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
8.3.3 Japan Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
8.3.4 South Korea Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
8.3.5 India Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
8.3.7 Australia Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
9 South America by Country, by Type, and by Application
9.1 South America Chronic Liver Diseases Therapeutics Revenue by Type (2017-2028)
9.2 South America Chronic Liver Diseases Therapeutics Revenue by Application (2017-2028)
9.3 South America Chronic Liver Diseases Therapeutics Market Size by Country
9.3.1 South America Chronic Liver Diseases Therapeutics Revenue by Country (2017-2028)
9.3.2 Brazil Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
9.3.3 Argentina Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Chronic Liver Diseases Therapeutics Revenue by Type (2017-2028)
10.2 Middle East & Africa Chronic Liver Diseases Therapeutics Revenue by Application (2017-2028)
10.3 Middle East & Africa Chronic Liver Diseases Therapeutics Market Size by Country
10.3.1 Middle East & Africa Chronic Liver Diseases Therapeutics Revenue by Country (2017-2028)
10.3.2 Turkey Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
10.3.4 UAE Chronic Liver Diseases Therapeutics Market Size and Forecast (2017-2028)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
List of TablesList of Tables
Table 1. Global Chronic Liver Diseases Therapeutics Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Chronic Liver Diseases Therapeutics Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Chronic Liver Diseases Therapeutics Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Chronic Liver Diseases Therapeutics Revenue (USD Million) by Region (2017-2022)
Table 5. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Region (2023-2028)
Table 6. Astellas Pharma Corporate Information, Head Office, and Major Competitors
Table 7. Astellas Pharma Major Business
Table 8. Astellas Pharma Chronic Liver Diseases Therapeutics Product and Solutions
Table 9. Astellas Pharma Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 11. Bristol-Myers Squibb Major Business
Table 12. Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Product and Solutions
Table 13. Bristol-Myers Squibb Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Gilead Sciences Corporate Information, Head Office, and Major Competitors
Table 15. Gilead Sciences Major Business
Table 16. Gilead Sciences Chronic Liver Diseases Therapeutics Product and Solutions
Table 17. Gilead Sciences Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 19. GlaxoSmithKline Major Business
Table 20. GlaxoSmithKline Chronic Liver Diseases Therapeutics Product and Solutions
Table 21. GlaxoSmithKline Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. F. Hoffmann-La Roche Corporate Information, Head Office, and Major Competitors
Table 23. F. Hoffmann-La Roche Major Business
Table 24. F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Product and Solutions
Table 25. F. Hoffmann-La Roche Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Merck Corporate Information, Head Office, and Major Competitors
Table 27. Merck Major Business
Table 28. Merck Chronic Liver Diseases Therapeutics Product and Solutions
Table 29. Merck Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Novartis Corporate Information, Head Office, and Major Competitors
Table 31. Novartis Major Business
Table 32. Novartis Chronic Liver Diseases Therapeutics Product and Solutions
Table 33. Novartis Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Sanofi Corporate Information, Head Office, and Major Competitors
Table 35. Sanofi Major Business
Table 36. Sanofi Chronic Liver Diseases Therapeutics Product and Solutions
Table 37. Sanofi Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Pfizer Corporate Information, Head Office, and Major Competitors
Table 39. Pfizer Major Business
Table 40. Pfizer Chronic Liver Diseases Therapeutics Product and Solutions
Table 41. Pfizer Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Takeda Pharmaceutical Corporate Information, Head Office, and Major Competitors
Table 43. Takeda Pharmaceutical Major Business
Table 44. Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Product and Solutions
Table 45. Takeda Pharmaceutical Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. Bausch Health Corporate Information, Head Office, and Major Competitors
Table 47. Bausch Health Major Business
Table 48. Bausch Health Chronic Liver Diseases Therapeutics Product and Solutions
Table 49. Bausch Health Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. Theratechnologies Corporate Information, Head Office, and Major Competitors
Table 51. Theratechnologies Major Business
Table 52. Theratechnologies Chronic Liver Diseases Therapeutics Product and Solutions
Table 53. Theratechnologies Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 55. Alnylam Pharmaceuticals Major Business
Table 56. Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Product and Solutions
Table 57. Alnylam Pharmaceuticals Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. Protagonist Therapeutics Corporate Information, Head Office, and Major Competitors
Table 59. Protagonist Therapeutics Major Business
Table 60. Protagonist Therapeutics Chronic Liver Diseases Therapeutics Product and Solutions
Table 61. Protagonist Therapeutics Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Dicerna Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 63. Dicerna Pharmaceuticals Major Business
Table 64. Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Product and Solutions
Table 65. Dicerna Pharmaceuticals Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. Endo International Corporate Information, Head Office, and Major Competitors
Table 67. Endo International Major Business
Table 68. Endo International Chronic Liver Diseases Therapeutics Product and Solutions
Table 69. Endo International Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Provectus Biopharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 71. Provectus Biopharmaceuticals Major Business
Table 72. Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Product and Solutions
Table 73. Provectus Biopharmaceuticals Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. MAX BioPharma Corporate Information, Head Office, and Major Competitors
Table 75. MAX BioPharma Major Business
Table 76. MAX BioPharma Chronic Liver Diseases Therapeutics Product and Solutions
Table 77. MAX BioPharma Chronic Liver Diseases Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Global Chronic Liver Diseases Therapeutics Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 79. Global Chronic Liver Diseases Therapeutics Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 80. Breakdown of Chronic Liver Diseases Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 81. Chronic Liver Diseases Therapeutics Players Head Office, Products and Services Provided
Table 82. Chronic Liver Diseases Therapeutics Mergers & Acquisitions in the Past Five Years
Table 83. Chronic Liver Diseases Therapeutics New Entrants and Expansion Plans
Table 84. Global Chronic Liver Diseases Therapeutics Revenue (USD Million) by Type (2017-2022)
Table 85. Global Chronic Liver Diseases Therapeutics Revenue Share by Type (2017-2022)
Table 86. Global Chronic Liver Diseases Therapeutics Revenue Forecast by Type (2023-2028)
Table 87. Global Chronic Liver Diseases Therapeutics Revenue by Application (2017-2022)
Table 88. Global Chronic Liver Diseases Therapeutics Revenue Forecast by Application (2023-2028)
Table 89. North America Chronic Liver Diseases Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 90. North America Chronic Liver Diseases Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 91. North America Chronic Liver Diseases Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 92. North America Chronic Liver Diseases Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 93. North America Chronic Liver Diseases Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 94. North America Chronic Liver Diseases Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 95. Europe Chronic Liver Diseases Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 96. Europe Chronic Liver Diseases Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 97. Europe Chronic Liver Diseases Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 98. Europe Chronic Liver Diseases Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 99. Europe Chronic Liver Diseases Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 100. Europe Chronic Liver Diseases Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 101. Asia-Pacific Chronic Liver Diseases Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 102. Asia-Pacific Chronic Liver Diseases Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 103. Asia-Pacific Chronic Liver Diseases Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 104. Asia-Pacific Chronic Liver Diseases Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 105. Asia-Pacific Chronic Liver Diseases Therapeutics Revenue by Region (2017-2022) & (USD Million)
Table 106. Asia-Pacific Chronic Liver Diseases Therapeutics Revenue by Region (2023-2028) & (USD Million)
Table 107. South America Chronic Liver Diseases Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 108. South America Chronic Liver Diseases Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 109. South America Chronic Liver Diseases Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 110. South America Chronic Liver Diseases Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 111. South America Chronic Liver Diseases Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 112. South America Chronic Liver Diseases Therapeutics Revenue by Country (2023-2028) & (USD Million)
Table 113. Middle East & Africa Chronic Liver Diseases Therapeutics Revenue by Type (2017-2022) & (USD Million)
Table 114. Middle East & Africa Chronic Liver Diseases Therapeutics Revenue by Type (2023-2028) & (USD Million)
Table 115. Middle East & Africa Chronic Liver Diseases Therapeutics Revenue by Application (2017-2022) & (USD Million)
Table 116. Middle East & Africa Chronic Liver Diseases Therapeutics Revenue by Application (2023-2028) & (USD Million)
Table 117. Middle East & Africa Chronic Liver Diseases Therapeutics Revenue by Country (2017-2022) & (USD Million)
Table 118. Middle East & Africa Chronic Liver Diseases Therapeutics Revenue by Country (2023-2028) & (USD Million)
List of Figures
Figure 1. Chronic Liver Diseases Therapeutics Picture
Figure 2. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Type in 2021
Figure 3. Chemotherapy Drugs
Figure 4. Targeted Therapy
Figure 5. Vaccines
Figure 6. Antiviral Drugs
Figure 7. Immunoglobulins
Figure 8. Corticosteroids
Figure 9. Others
Figure 10. Chronic Liver Diseases Therapeutics Revenue Market Share by Application in 2021
Figure 11. Hospital Pharmacies Picture
Figure 12. Retail Pharmacies Picture
Figure 13. Online Pharmacies Picture
Figure 14. Global Chronic Liver Diseases Therapeutics Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 15. Global Chronic Liver Diseases Therapeutics Revenue and Forecast (2017-2028) & (USD Million)
Figure 16. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Region (2017-2028)
Figure 17. Global Chronic Liver Diseases Therapeutics Revenue Market Share by Region in 2021
Figure 18. North America Chronic Liver Diseases Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 19. Europe Chronic Liver Diseases Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 20. Asia-Pacific Chronic Liver Diseases Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 21. South America Chronic Liver Diseases Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 22. Middle East and Africa Chronic Liver Diseases Therapeutics Revenue (USD Million) and Growth Rate (2017-2028)
Figure 23. Chronic Liver Diseases Therapeutics Market Drivers
Figure 24. Chronic Liver Diseases Therapeutics Market Restraints
Figure 25. Chronic Liver Diseases Therapeutics Market Trends
Figure 26. Astellas Pharma Recent Developments and Future Plans
Figure 27. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 28. Gilead Sciences Recent Developments and Future Plans
Figure 29. GlaxoSmithKline Recent Developments and Future Plans
Figure 30. F. Hoffmann-La Roche Recent Developments and Future Plans
Figure 31. Merck Recent Developments and Future Plans
Figure 32. Novartis Recent Developments and Future Plans
Figure 33. Sanofi Recent Developments and Future Plans
Figure 34. Pfizer Recent Developments and Future Plans
Figure 35. Takeda Pharmaceutical Recent Developments and Future Plans
Figure 36. Bausch Health Recent Developments and Future Plans
Figure 37. Theratechnologies Recent Developments and Future Plans
Figure 38. Alnylam Pharmaceuticals Recent Developments and Future Plans
Figure 39. Protagonist Therapeutics Recent Developments and Future Plans
Figure 40. Dicerna Pharmaceuticals Recent Developments and Future Plans
Figure 41. Endo International Recent Developments and Future Plans
Figure 42. Provectus Biopharmaceuticals Recent Developments and Future Plans
Figure 43. MAX BioPharma Recent Developments and Future Plans
Figure 44. Global Chronic Liver Diseases Therapeutics Revenue Share by Players in 2021
Figure 45. Chronic Liver Diseases Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 46. Global Top 3 Players Chronic Liver Diseases Therapeutics Revenue Market Share in 2021
Figure 47. Global Top 10 Players Chronic Liver Diseases Therapeutics Revenue Market Share in 2021
Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 49. Global Chronic Liver Diseases Therapeutics Revenue Share by Type in 2021
Figure 50. Global Chronic Liver Diseases Therapeutics Market Share Forecast by Type (2023-2028)
Figure 51. Global Chronic Liver Diseases Therapeutics Revenue Share by Application in 2021
Figure 52. Global Chronic Liver Diseases Therapeutics Market Share Forecast by Application (2023-2028)
Figure 53. North America Chronic Liver Diseases Therapeutics Sales Market Share by Type (2017-2028)
Figure 54. North America Chronic Liver Diseases Therapeutics Sales Market Share by Application (2017-2028)
Figure 55. North America Chronic Liver Diseases Therapeutics Revenue Market Share by Country (2017-2028)
Figure 56. United States Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Canada Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Mexico Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Europe Chronic Liver Diseases Therapeutics Sales Market Share by Type (2017-2028)
Figure 60. Europe Chronic Liver Diseases Therapeutics Sales Market Share by Application (2017-2028)
Figure 61. Europe Chronic Liver Diseases Therapeutics Revenue Market Share by Country (2017-2028)
Figure 62. Germany Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. France Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. United Kingdom Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Russia Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Italy Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Asia-Pacific Chronic Liver Diseases Therapeutics Sales Market Share by Type (2017-2028)
Figure 68. Asia-Pacific Chronic Liver Diseases Therapeutics Sales Market Share by Application (2017-2028)
Figure 69. Asia-Pacific Chronic Liver Diseases Therapeutics Revenue Market Share by Region (2017-2028)
Figure 70. China Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Japan Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. South Korea Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. India Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Southeast Asia Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Australia Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South America Chronic Liver Diseases Therapeutics Sales Market Share by Type (2017-2028)
Figure 77. South America Chronic Liver Diseases Therapeutics Sales Market Share by Application (2017-2028)
Figure 78. South America Chronic Liver Diseases Therapeutics Revenue Market Share by Country (2017-2028)
Figure 79. Brazil Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Argentina Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. Middle East and Africa Chronic Liver Diseases Therapeutics Sales Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Chronic Liver Diseases Therapeutics Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Chronic Liver Diseases Therapeutics Revenue Market Share by Country (2017-2028)
Figure 84. Turkey Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. Saudi Arabia Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. UAE Chronic Liver Diseases Therapeutics Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 87. Methodology
Figure 88. Research Process and Data Source
Published By : GlobalInfoResearch
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
